GlassScriptPhysician profile
Steven E Kane
NPI 1467712224
$62,626.49
in general payments reported to CMS, 2019-2025
24 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $252 · 2021: $4,168 · 2022: $291 · 2023: $22K · 2024: $22K · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Travel and Lodging: $13K · Food and Beverage: $3,483 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,154.15 |
| Travel and Lodging | $12,979.78 |
| Food and Beverage | $3,482.62 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $39,944.37 | 2022-2025 | Envista Mx60 Iol, Trulign Iol, Stellaris Elite |
| Biotissue Holdings INC. | $16,448.22 | 2019-2025 | |
| Rxsight INC | $4,245.15 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $326.61 | 2019-2024 | Cequa |
| Alcon Vision LLC | $303.62 | 2021-2025 | Tryptyr, Eysuvis, Clareon Panoptix Pro |
| Abbvie INC. | $279.61 | 2023-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $178.82 | 2020-2024 | Tecnis Iol |
| Kala Pharmaceuticals, INC. | $130.97 | 2019-2020 | |
| Ocular Therapeutix, INC. | $105.90 | 2023-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $85.33 | 2019-2023 | |
| Rayner Intraocular Lenses Limited | $82.54 | 2024-2025 | Omidria |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.41 | 2019-2021 | |
| Harrow Eye, LLC | $76.32 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $59.88 | 2021-2024 | Omni Surgical System |
| Dompe US, INC. | $59.71 | 2024-2025 | Oxervate |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $48.52 | 2020-2025 | Idosetr |
| Oyster Point Pharma, INC. | $47.41 | 2022-2025 | Ryzumvi, Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $30.21 | 2024 | Xdemvy |
| Thea Pharma INC. | $21.04 | 2022 | |
| Alimera Sciences, INC. | $16.93 | 2019 | |
| Shire North American Group INC | $15.66 | 2019 | |
| Allergan, INC. | $15.51 | 2021 | |
| New World Medical,INC. | $13.50 | 2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Coopervision INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.